Data / Drug companies / Obagi Cosmeceuticals LLC
Obagi Cosmeceuticals LLC: 51 products in the FDA NDC directory, labeler code 62032
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Obagi Cosmeceuticals LLC (labeler code 62032) lists 51 products in the FDA National Drug Code Directory, covering 21 finished drugs by generic name. By type: 33 over the counter drugs, 18 prescription drugs. Its main marketing category is other unapproved drugs. The newest product started marketing on April 28, 2026.
The request: Watch Obagi Cosmeceuticals LLC (FDA labeler code 62032): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 62032
- Products in commercial distribution
- 51
- Packages
- 50
- Finished drugs by generic name
- 21
- Prescription products
- 18
- Over the counter products
- 33
- Flagged as original packager
- 51 of 51 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- January 26, 1973
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Other unapproved drugs | 25 | 49% |
| Over the counter monograph drugs | 22 | 43.1% |
| New drug applications (NDA) | 3 | 5.9% |
| Authorized generics (NDA) | 1 | 2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 33 | 64.7% |
| Prescription drugs | 18 | 35.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Homosalate, octisalate, and zinc oxide | 7 | 2 |
| Hydroquinone, homosalate, octisalate, zinc oxide | 6 | 1 |
| Hydroquinone | 5 | 12 |
| Tretinoin | 4 | 28 |
| Hydroquinone, homosalate, octisalate, and zinc oxide | 3 | 1 |
| Salicylic acid | 3 | 330 |
| Homosalate, octisalate, zinc oxide | 3 | 11 |
| Hydroquinone, titanium dioxide, zinc oxide | 3 | 1 |
| Titanium dioxide, zinc oxide | 2 | 255 |
| Titanium dioxide and zinc oxide | 2 | 46 |
| Salicylic acid, titanium dioxide, and zinc oxide | 1 | 1 |
| Zinc oxide | 1 | 595 |
| Avobenzone, octinoxate, octisalate, and oxybenzone | 1 | 2 |
| Hydroquinone, octisalate and zinc oxide | 1 | 1 |
| Glycerin | 1 | 56 |
| Avobenzone, homosalate, octisalate, and octocrylene | 1 | 23 |
| Octinoxate and zinc oxide | 1 | 8 |
| Salicylic acid and benzoyl peroxide | 1 | 2 |
| Hydroquinone, titanium dioxide, and zinc oxide | 1 | 1 |
| Hydroquinone, octinoxate, and oxybenzone | 1 | 1 |
| Benzoyl peroxide | 1 | 82 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Kit | 30 | 58.8% |
| Cream | 10 | 19.6% |
| Lotion | 4 | 7.8% |
| Liquid | 3 | 5.9% |
| Gel | 2 | 3.9% |
| Solution | 1 | 2% |
| Cloth | 1 | 2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sun Shield Mineral UV Barrier Protect Broad Spectrum SPF 40 Sunscreen | 62032-002 | Lotion | Over the counter monograph drugs | April 28, 2026 |
| Lip Therapy Soothe and Protect Lip Treatment Broad Spectrum SPF 30 | 62032-926 | Gel | Over the counter monograph drugs | November 1, 2025 |
| SUZANOBAGIMD Acne Cleansing Wipes | 62032-617 | Cloth | Over the counter monograph drugs | July 1, 2025 |
| Obagi Nu-Derm Fx System Normal-Oily Skin Transformation Complexion Brightening System | 62032-925 | Kit | Over the counter monograph drugs | June 25, 2025 |
| Obagi Nu-Derm Fx System Normal-Dry Skin Transformation Complexion Brightening System | 62032-924 | Kit | Over the counter monograph drugs | June 25, 2025 |
| Obagi-C C-Rx system Normal-oily skin Intervention | 62032-923 | Kit | Other unapproved drugs | June 25, 2025 |
| Obagi Nu-Derm System Normal-Dry Skin Transformation | 62032-918 | Kit | Other unapproved drugs | June 25, 2025 |
| Obagi Medical Way to Glow Kit | 62032-690 | Kit | Over the counter monograph drugs | March 20, 2023 |
| Obagi Medical Back to Basics (Including Obagi Medical Professional-C Serum 15) | 62032-694 | Kit | Over the counter monograph drugs | April 1, 2022 |
| Obagi Medical Back to Basics (Including Obagi Medical Professional-C Serum 20) | 62032-693 | Kit | Over the counter monograph drugs | April 1, 2022 |
| Obagi Skintrinsiq Firming Protocol | 62032-910 | Kit | Over the counter monograph drugs | August 1, 2021 |
| Obagi Skintrinsiq Clarifiying Protocol | 62032-909 | Kit | Over the counter monograph drugs | August 1, 2021 |
| Obagi Skintrinsiq Antioxidant Protocol | 62032-907 | Kit | Over the counter monograph drugs | August 1, 2021 |
| Obagi Skintrinsiq Antioxidant Protocol | 62032-906 | Kit | Over the counter monograph drugs | August 1, 2021 |
| Obagi Skintrinsiq Brightening Protocol | 62032-905 | Kit | Over the counter monograph drugs | August 1, 2021 |
| Obagi Nu-Derm System Normal-Oily Skin Transformation | 62032-919 | Kit | Other unapproved drugs | June 25, 2021 |
| Obagi Nu-Derm System Normal-Oily Skin Transformation | 62032-912 | Kit | Other unapproved drugs | June 25, 2021 |
| Obagi Nu-Derm System Normal-Dry Skin Transformation Kit | 62032-911 | Kit | Other unapproved drugs | June 25, 2021 |
| Obagi Medical Physical Defense Broad Spectrum Mineral Sunscreen SPF 50 by SUZANOBAGIMD | 62032-608 | Cream | Over the counter monograph drugs | April 1, 2020 |
| Obagi-C C-Rx System Normal-Dry Skin Intervention | 62032-922 | Kit | Other unapproved drugs | December 2, 2019 |
| Obagi-C Fx System Normal-Oily Skin Brightening System with Arbutin | 62032-917 | Kit | Other unapproved drugs | December 2, 2019 |
| Obagi-C C-Rx System Normal-Dry Skin Intervention | 62032-916 | Kit | Other unapproved drugs | December 2, 2019 |
| Obagi-C C-Rx System Normal-Oily Skin Intervention | 62032-915 | Kit | Other unapproved drugs | December 2, 2019 |
| Obagi Nu-Derm System Normal-Oily Skin Transformation Trial | 62032-914 | Kit | Other unapproved drugs | December 2, 2019 |
| Obagi Nu-Derm System Normal-Dry Skin Transformation Trial | 62032-913 | Kit | Other unapproved drugs | December 2, 2019 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.